Open AccessIn vitro Antimicrobial Activity of Ethanolic Leaf Extracts of Hibiscus Asper Hook. F. and Hibiscus Sabdariffa L. on some Pathogenic Bacteria
Author(s) -
Joseph Olowo Arogbodo,
Oyetayo Bolanle Faluyi,
Festus Omotere Igbe
Publication year - 2021
Publication title -
journal of scientific research in medical and biological sciences
Language(s) - English
Resource type - Journals
eISSN - 2709-1511
pISSN - 2709-0159
DOI - 10.47631/jsrmbs.v2i3.304
Subject(s) - hibiscus sabdariffa , antimicrobial , biology , agar diffusion test , moraxella catarrhalis , traditional medicine , pathogenic bacteria , microbiology and biotechnology , minimum inhibitory concentration , proteus vulgaris , bacteria , antibacterial activity , staphylococcus aureus , horticulture , medicine , genetics
Purpose: The study aims to assess the antimicrobial activity of ethanolic leaf extracts of Hibiscus asper and Hibiscus sabdariffa against eight bacterial isolates.Materials and Methods: An in vitro Antimicrobial activity of ethanolic leaf extract of the two plants against eight nosocomical and pathogenic bacteria viz; Pseudomonas aeruginosa (PAE), Proteus vulgaris (PVU), Klebsiella aerogenes (KAE), Staphylococcus aureus (SAU), Bacillus cereus (BCE), Escherichia coli (ECO), Moraxella catarrhalis (MCA) and Salmonella typhi (STY) was carried out using agar well diffusion assay with the concentration range of 3.13 – 100 mg/mL. Results: H. asper and H. sabdariffa showed significant difference (p ECO (11.67 ± 0.58b) >SAU (7.67 ± 0.58c) >PAE (6.67 ± 0.58d) >STY (5.67 ± 0.58e) while that of H. sabdariffa was in the order BCE (15.33 ± 1.15a) > MCA (11.33 ± 1.15b) > SAU (11.00 ± 1.00bc) > KAE (9.67 ± 0.58c) > PAE (8.00 ± 1.00d) >PVU (7.67 ± 0.57e). PVU, KAE and MCA were resistant to the extract of H. asper while only STY was resistant to that of H. sabdariffa. Conclusion: H. sabdariffa extract demonstrated higher antimicrobial activity against the selected bacterial isolates than H. asper. However, the two extracts minimum inhibition concentrations (MICs) ranged from 25 mg/mL to 12.5 mg/mL. This is worthy of further exploration by pharmacological industries in the formulation of potent broad spectrum antibiotics for combating the present health challenge due to antimicrobial resistance.